Aryl ether-substituted heterocyclic compounds as glpir agonists

A compound of Formula (IE), pharmaceutically acceptable salts, or enantiomers thereof,

• wherein,
• =represents a single bond;
• X represents —O—;
• X′ represents —C(Rd1)(Rd2)—;
• L represents —O—;
• X1 represents —N—;
• X3 represents —N—;
• X8 represents —CR5— or —N—;
• R is 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated heterocyclyl, or 3- to 8-membered saturated or partially saturated cycloalkyl, and wherein the heteroaryl, heterocyclyl, and cycloalkyl are optionally substituted with one to multiple substituent groups independently selected from methyl, ethyl, propyl, butyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl, and hexyl;
• each R1 is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, C1-10 alkyl, halogen-substituted C1-10 alkyl, deuterium substituted C1-10 alkyl, and —COOH;
• each R4 is the same or different and is independently selected from hydrogen, deuterium, halogen, C1-10 alkyl, and C1-10 alkoxy;
• R5 is selected from hydrogen, deuterium, halogen, CN, C1-10 alkyl, C2-10 alkynyl, and C1-10 alkoxy;
• each R6 is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, C1-10 alkyl, C2-10 alkynyl, and C1-10 alkoxy;
• Rd1 and Rd2 are independently selected from hydrogen, deuterium, halogen, and C1-10 alkyl;
• m is an integer selected from 1 and 2;
• n is an integer selected from 0, 1 and 2;
• and
• q is an integer selected from 0, 1 and 2.